HuCNS-SC (StemCells)
Overview
Pharmacology
Authors
Affiliations
HuCNS-SC, a proprietary human neural stem cells product, is being developed as a cellular therapy for the potential treatment of Batten disease, one of a group of disorders known as neural ceroid lipofuscinoses (NCL). Developer StemCells is also investigating the therapy for spinal cord injury and other central nervous system disorders, such as demyelinating disease, stroke and Alzheimer's disease. A phase I trial of HuCNS-SC for infantile and late-infantile NCL has been initiated, following the March 2006 U.S. Food and Drug Administration approval of StemCells' investigational new drug application.
Sareen D, Gowing G, Sahabian A, Staggenborg K, Paradis R, Avalos P J Comp Neurol. 2014; 522(12):2707-28.
PMID: 24610630 PMC: 4070510. DOI: 10.1002/cne.23578.
Concise review: self-renewal in the central nervous system: neural stem cells from embryo to adult.
De Filippis L, Binda E Stem Cells Transl Med. 2012; 1(4):298-308.
PMID: 23197809 PMC: 3659692. DOI: 10.5966/sctm.2011-0045.
Ferrari D, Zalfa C, Nodari L, Gelati M, Carlessi L, Delia D Cell Mol Life Sci. 2011; 69(7):1193-210.
PMID: 22076651 PMC: 11115189. DOI: 10.1007/s00018-011-0873-5.
Neural stem cell transplantation as a therapeutic approach for treating lysosomal storage diseases.
Shihabuddin L, Cheng S Neurotherapeutics. 2011; 8(4):659-67.
PMID: 21904790 PMC: 3250293. DOI: 10.1007/s13311-011-0067-8.
Lu J, Hu J, Hofmann S Mol Genet Metab. 2009; 99(4):374-8.
PMID: 20036592 PMC: 2839016. DOI: 10.1016/j.ymgme.2009.12.002.